← Back to screener

Cullinan Therapeutics, Inc. CGEM

Rank #1807 · Nasdaq · $0.9B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
41.7
P/E
-5.5
P/B
1.56
ROE
-28.4%
Op. Margin
–%
Debt Ratio
5%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -5.5x, P/B 1.56x. Ranks in the top 57% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -28.4%. Ranks in the top 84% of the universe.

Safety ★★★★★
Excellent

Debt ratio 5%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.1B$-0.1B$0.1B–15
2022$0.0B$-0.1B$-0.1B$0.4B-358.73
2023–$0.1B$0.1B$0.5B–5
2024–$-0.2B$-0.2B$0.5B–7
2025–$-0.2B$-0.2B$0.6B–5

← See the full screener